$5.07
+0.02(0.40%)
Mkt Cap $57M
$4.97
$17.90
52-Week Range
At a Glance
AI-generatedImageneBio Inc reported a net loss of $45.3 million for fiscal year 2025, with minimal revenue of $800,000 from license agreements.
8-K
ImageneBio Inc filed an 8-K on March 10, 2026, furnishing Item 2.02 Results of Operations via Exhibit 99.1 Press Release. The filing includes the Cover Page Interactive Data File as Exhibit 104.$57M
Market Cap
—
Revenue
-$43M
Net Income
Employees10
Fundamentals
How The Business Makes Money
Clinical-stage biotechnology company developing differentiated therapies for immunological/autoimmune & inflammatory (I&I) diseases, notably non‑depleting anti‑OX40 monoclonal antibody IMG‑007 in Phase 2b for atopic dermatitis
Industry Biotechnology
Activity
What Changed Recently
Analyst View
Company Profile
CIK0001835579
ISINUS45175G2075
CUSIP45175G207
Phone858 345 6265
Address12526 High Bluff Drive, Suite 345, San Diego, CA 92130, San Diego, CA, 92130, US
SEC EDGAR